Search Bar & Filters
Found 54 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.
Actively Recruiting
Researchers are studying the long-term safety and effectiveness of Inpegsomatropin Injection in children with Idiopathic Short Stature ISS who have completed previous Phase II clinical trials. This open-label, single-arm extension study allows participants and their guardians to decide on continued participation after a thorough evaluation of benefits and risks. The study is conducted at multiple centers and focuses on those who have already undergone initial treatment phases for ISS. Participants who qualify will receive weekly injections of Inpegsomatropin at a dose of 280 micrograms per kilogram under the skin. This treatment continues until the participant reaches near-adult height. After finishing the treatment period, participants enter a follow-up phase where their growth, development, medication use, and safety are monitored through outpatient visits. This process aims to gather detailed data on the long-term effects of the study drug. Throughout the study, participants will have regular assessments for safety, including monitoring of adverse events every 13 weeks during the first year and then yearly for up to 16 years. Researchers will also track changes in height, height velocity, bone age compared to chronological age, insulin-like growth factor-1 levels, and final height. The total participation period spans several years, allowing thorough observation of growth and development outcomes.
Actively Recruiting
Researchers are evaluating new treatments for people with locally advanced or metastatic urothelial cancer UC that has worsened after previous therapies. This phase 3 trial aims to find out if sacituzumab tirumotecan sac-TMT, an investigational drug given by intravenous infusion, can help patients live longer compared to standard non-platinum chemotherapy options. The study is sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan at 4 mgkg every two weeks via IV infusion or one of three chemotherapy drugspaclitaxel, docetaxel, or vinfluninegiven every three weeks by IV infusion. Treatment continues until the disease progresses or side effects become unacceptable. Rescue medications may be given as needed according to approved guidelines during treatment. During the trial, participants will have regular assessments including imaging to measure disease status and evaluations of side effects and quality of life. The main outcome measured is overall survival up to about 40 months, along with secondary outcomes like progression-free survival, response rates, duration of response, and changes in quality of life scores. Safety and adverse events will be monitored throughout, with the study lasting until April 2030.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of TQH3906 capsules, a once-daily oral medication, in adults aged 18 to 75 with moderate to severe plaque psoriasis. This multicenter, randomized, double-blind, placebo- and active-controlled Phase III trial compares TQH3906 with deucravacitinib and placebo. TQH3906 selectively inhibits TYK2, targeting inflammatory pathways involved in psoriasis, aiming to support its approval for treating this condition. Participants are randomly assigned in a 221 ratio to receive TQH3906 capsules 24 mg, deucravacitinib tablets 6 mg, or placebos matching each drug during a 16-week double-blind treatment phase. After this, all participants enter a 36-week open-label extension where they receive TQH3906 capsules alone. Following treatment, there is a 4-week safety follow-up period to monitor any lasting effects. Throughout the study, participants undergo regular assessments including the static Physicians Global Assessment sPGA and Psoriasis Area and Severity Index PASI to measure skin improvement up to 16 and 52 weeks. Additional evaluations focus on scalp, nail, and palmoplantar psoriasis, quality of life via the Dermatology Life Quality Index DLQI, and drug levels in the body. Safety is closely monitored during and after the treatment periods to gather comprehensive data over a year.
Actively Recruiting
Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.
Actively Recruiting
Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of combining selinexor with azacitidine and venetoclax in adults newly diagnosed with acute myeloid leukemia AML who have not received prior treatment. The study is a prospective, single-arm, multi-center clinical trial focusing on patients who are either ineligible for or refuse intensive chemotherapy. It is designed to gather data on how well this combination works and its safety profile in this patient group. Participants will receive selinexor orally at 60 mg on days 3, 10, and 17 azacitidine intravenously at 75 mgm2 on days 1-3, 8-9, and 15-16 and venetoclax orally starting at 100 mg on day 1, increasing to 200 mg on day 2, and 400 mg on days 3-14 within each 28-day treatment cycle. Those who achieve complete remission may undergo a transplant at any time, while others will continue treatment until the disease progresses or unacceptable side effects occur. During the study, participants will be closely monitored for treatment response and safety through assessments including remission rates up to about two years. Secondary measures include overall survival, response rates, minimal residual disease negativity, and recurrence-free survival over approximately four years. The total participation time varies based on individual outcomes, with ongoing evaluations to track effectiveness and side effects throughout the study period.
Actively Recruiting
Researchers are studying the safety and effectiveness of TQB2102 for injection in patients with HER2-positive biliary tract cancer. This includes patients with locally advanced or metastatic forms of the disease who have experienced failure of 1-2 prior systemic therapies. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. and spans phases 1 and 2 to evaluate dosing, safety, and immune response. Participants receive TQB2102, a HER2 dual-antibody-drug conjugate, by intravenous infusion every three weeks in cycles of 21 days. Treatment involves 6 to 8 cycles, with ongoing monitoring for adverse events and response to therapy. The study does not use masking or placebo controls. During the trial, participants undergo assessments for tumor response, disease control, survival, and side effects from the time of consent until 28 days after the last dose or the start of a new antitumor therapy. Follow-up includes evaluations up to 36 weeks for outcomes like progression-free and overall survival. Participants also provide tumor tissue samples for HER2 testing and are monitored for immune reactions and safety throughout the study.
1-10 of 54
1